A drug used to
treat chronic lymphocytic leukemia, small lymphocytic
lymphoma, and Waldenstrom macroglobulinemia (a type of
non-Hodgkin lymphoma). It is also used to treat mantle cell
lymphoma and marginal zone lymphoma in patients who have
received at least one other treatment. It is also being
studied in the treatment of other types of cancer.
Ibrutinib blocks a protein
called Bruton’s tyrosine kinase (BTK), which may help keep
cancer cells from growing. It is a type of tyrosine kinase
inhibitor. Also called Imbruvica.